Niagen Bioscience’s promising results to benefit long COVID individuals with relief to their health

Announcement

Niagen Bioscience, Inc., the leading global authority on NAD+ (nicotinamide adenine dinucleotide) with an aim on the science of healthy ageing, have shared dedicated results from the best-in-class first clinical trial officially published latest in ‘The Lancet' peer-reviewed journal eClinicalMedicine’ elaborating that regular supplementation with Niagen. Niagen Biosciences’ renowned nicotinamide riboside (NR) ingredient prominently accelerated the NAD+ levels and enhanced executive fatigue, functioning, sleep quality and depression.

Following the comparison volume to the baseline levels, in few individuals suffered with long-term COVID, also called as ‘post-acute sequelae of SARS-CoV-2 infection (PASC). The double blind, placebo-controlled, randomised study in 58 participants was organised by the PhD, McCance Center for Brain Health at Massachusetts General Hospital and was formerly an Assistant Professor in the Department of Psychiatry, Edmarie Guzman-Velez.

Velez is now an Assistant Professor in the Department of Neurology at the Robert Wood Johnson Medical School and the Center for Health Aging Research (CHAR) at the Institute for Health, Rutgers University.

Benefits of these promising results

The Long COVID has largely continued to affect a significant number of people across the globe, with no promising treatment available. Though later the vaccines and other medications came into force, but left the scars and triggered other conditions like sleep, fatigue and depression. Following this, the Niagen’s result proves to serve best for these triggered conditions.

As per the U.S Centers for Disease Control and Prevention, in 2024, between August and September, around 5.3% of adults in the U.S were found under the condition of long-term COVID.

What links Long COVID and NAD+?

The Long COVID symptoms endure months or years after the infection, involving breathlessness, cognitive impairment or brain fog, common fatigue, anxiety, muscle aches and depression. The rapid proof advises that communicating mechanisms underpin long COVID, consisting of mitochondrial dysfunction, disrupted cellular energy metabolism, depletion of NAD+, oxidative stress and immune dysregulation, which is a potent molecular complex for repair and cellular energy.

The Chief Executive Officer of Niagen Bioscience, Rob Fried, said, “These findings elaborate that the Niagen NR supplementation for ten weeks improved long COVID symptoms of depression, fatigue and sleep quality and elevated NAD+ levels, proving excellence than the symptoms shown before treatment. Advancing the science of cellular health is our mission, and we are grateful to see Niagen NR considered in research exploring the long-term impact of COVID-19.”